ArticleEsophagus : official journal of the Japan Esophageal Society2025
Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study.
Article in Esophagus : official journal of the Japan Esophageal Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Outcomes of First-Line Immune Checkpoint Inhibitor-Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer.Annals of surgical oncology · 2026Article
- Risk Stratification of Postoperative Recurrence After Adjuvant Nivolumab for Resected Locally Advanced Esophageal Cancer: A Real-World Study.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimNivolumab, approved for adjuvant therapy in resected esophageal cancer, is typically administered at 240 mg every 2 weeks (Q2W) or 480 mg every 4 weeks (Q4W). However, data on the 480 mg Q4W regimen as an initial therapy are limited. In this study, we evaluated its safety and efficacy.
methodsThis prospective cohort study included 50 patients with pathologically confirmed lymph node metastases who underwent radical esophagectomy following preoperative therapy. All patients received at least one dose of nivolumab (480 mg Q4W). The primary endpoint was the incidence of Grade 3 or higher nivolumab-related adverse events (AEs).
resultsOf the cohort, 88% (44/50) received preoperative chemotherapy. The pathological lymph node status was distributed as follows: ypN1 (42%), ypN2 (40%), and ypN3 (18%). A total of 26 patients (52%) completed one year of therapy. Therapy discontinuation occurred because of relapse (30%), nivolumab-related AEs (10%), or patient preference (8%). Nivolumab-related AEs occurred in 70% of the patients, with Grade 3 or higher AEs occurring in 8%. The most common AEs were skin-related reactions (30%), elevated aspartate aminotransferase levels (24%), fatigue (12%), hypothyroidism (12%), and hyperthyroidism (10%). The majority of AEs occurred during the first four cycles, whereas thyroid dysfunction, arthritis, and pulmonary AEs appeared even later. One- and two-year disease-free survival (DFS) rates were 78.0% and 52.2%, respectively. Patients aged < 65 years and those with ypN2 disease demonstrated better DFS.
conclusionAdjuvant nivolumab 480 mg Q4W may represent a potential treatment option with a manageable safety profile and favorable short-term DFS.
Indexed as
Identifiers
40484886What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.